黑料官网

header-logo
GettyImages-758308167-hero
Biostatistics
Ruta Brazauskas, PhD

Ruta Brazauskas, PhD

Associate Professor, Biostatistics

Locations

  • Biostatistics

Contact Information

Education

PhD, Biostatistics, 黑料官网, Milwaukee, WI, 2003
MS, Statistics, University of Texas at Dallas, Richardson, TX, 1999
BS, Applied Mathematics, Vilnius University, Lithuania, 1992

Research Experience

  • Survival Analysis

Research Interests

Dr. Ruta Brazauskas joined biostatistics in June 2008. Dr. Brazauskas’ research interests include survival analysis and competing risks. Most recent methodological work on the issues of paired studies in survival analysis was funded by the CTSA supplemental grant awarded to a group of faculty members at the Division. Her collaborative work is mostly focused on the outcomes of bone marrow transplantation (BMT) and in particular long-tern effects of the BMT. Dr. Brazauskas is the lead statistician of the Late Effects Working Committee and Health Policy Working Committee at the Center for International Bone Marrow Transplant Research. Her other collaborators include 黑料官网 physicians from various departments as well as researchers in the area of public health. In 2012, Dr. Brazauskas received the Graduate Student Association's Teacher of the Year Award for her exceptional teaching in Biostatistics.

Publications

  • (Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen D, Ferreri C, Dhakal B, Dhanda D, Harrison M, Kitali A, Landau H, Mirza AS, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Gowda L, Anderson LD Jr, Pasquini MC, Usmani S, Freeman CL.) Blood Adv. 2025 Apr 08;9(7):1587-1592 PMID: 39786391 PMCID: PMC11986210 SCOPUS ID: 2-s2.0-105002032521 01/09/2025

  • (Parikh TN, Peterson KJ, Brazauskas R, Calata JF, Peterson CY, Ludwig KA, Ridolfi TJ.) J Gastrointest Surg. 2025 Mar;29(3):101972 PMID: 39842769 SCOPUS ID: 2-s2.0-85216632412 01/23/2025

  • (Khan NI, Coleman KD, Nimmer M, Brazauskas R, Brousseau DC.) Am J Emerg Med. 2025 Mar;89:75-77 PMID: 39700883 SCOPUS ID: 2-s2.0-85212203942 12/20/2024

  • (Basir MA, McDonnell SM, Brazauskas R, Kim UO, Ahamed SI, McIntosh JJ, Pizur-Barnekow K, Pitt MB, Kruper A, Leuthner SR, Flynn KE.) Patient Educ Couns. 2025 Mar;132:108599 PMID: 39647248 PMCID: PMC11757045 SCOPUS ID: 2-s2.0-85211172216 12/09/2024

  • (Eapen M, Malec LM, Armant MA, Johnson BD, Shi Q, Xu H, Du LM, Jerkins JH, Duffy LJ, Bushman FD, Lee C, Petrichenko A, Hematti P, Brazauskas R, Jobe SM, Hari PN, Wilcox DA.) N Engl J Med. 2025 Jan 23;392(4):412-414 PMID: 39842018 PMCID: PMC11756741 SCOPUS ID: 2-s2.0-85216608254 01/22/2025

  • (McQueen RG, Aronowitz DI, Singh NM, Brazauskas R, Burstein D, White RM, Fuller S, Gaynor JW, Woods RK.) JTCVS Open. 2025 SCOPUS ID: 2-s2.0-86000368566 01/01/2025

  • (McDonnell SM, Flynn KE, Barnekow K, Kim UO, Brazauskas R, Ahamed SI, McIntosh JJ, Pitt MB, Leuthner SR, Kruper A, Basir MA.) PEC Innov. 2024 Dec 15;5:100346 PMID: 39434846 PMCID: PMC11491957 10/22/2024

  • (Feih J, Weierstahl K, Juul J, Brazauskas R, Held-Godgluck B, Rinka J.) J Pharm Technol. 2024 Oct;40(5):215-222 PMID: 39391327 PMCID: PMC11462938 10/11/2024

  • (Basir MA, McDonnell SM, Brazauskas R, Kim UO, Ahamed SI, McIntosh JJ, Pizur-Barnekow K, Pitt MB, Kruper A, Leuthner SR, Flynn KE.) medRxiv. 2024 Sep 12 PMID: 39314933 PMCID: PMC11419244 09/24/2024

  • (McDonnell SM, Flynn KE, Barnekow K, Kim UO, Brazauskas R, Ahamed SI, McIntosh JJ, Pitt MB, Leuthner SR, Kruper A, Basir MA.) PEC Innovation. 15 December 2024;5 SCOPUS ID: 2-s2.0-85205455964 12/15/2024

  • (Sheldon H, Duncan N, Singh A, Endrizzi S, Conrardy R, Brazauskas R, Peppard W.) Journal of Opioid Management. November 2024;20(6):471-486 SCOPUS ID: 2-s2.0-85213012660 11/01/2024

  • (Feih J, Weierstahl K, Juul J, Brazauskas R, Held-Godgluck B, Rinka J.) Journal of Pharmacy Technology. October 2024;40(5):215-222 SCOPUS ID: 2-s2.0-85201256037 10/01/2024

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 黑料官网’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.

Notice of Compliance with Laws and Commitment to Civil Rights
The 黑料官网 is committed to full compliance with all applicable federal, state, and local laws and regulations in the pursuit of our missions. Consistent with recent federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making. As part of this commitment, we are actively reviewing our policies and materials to ensure they align with federal nondiscrimination obligations.